Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan

[1]  P. Krammer,et al.  The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.

[2]  B. Gliniak,et al.  Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. , 1999, Cancer research.

[3]  E Springer,et al.  Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. , 1999, Cancer research.

[4]  P. Krammer,et al.  Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[5]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[6]  K. Okumura,et al.  Type I Interferons (IFNs) Regulate Tumor Necrosis Factor–related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of  Type I IFNs , 1999, The Journal of experimental medicine.

[7]  M. Degli-Esposti.  To die or not to die—the quest of the TRAIL receptors , 1999, Journal of leukocyte biology.

[8]  M. Nau,et al.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. , 1999, Cancer research.

[9]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[10]  C. Bokemeyer,et al.  Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience , 1999, Oncology.

[11]  Y. Yuasa,et al.  Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas. , 1998, Cancer letters.

[12]  T. Griffith,et al.  TRAIL: a molecule with multiple receptors and control mechanisms. , 1998, Current opinion in immunology.

[13]  T. Griffith,et al.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.

[14]  P. Hersey,et al.  TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. , 1998, Journal of immunology.

[15]  D. Ferrari,et al.  Apoptosis signaling by death receptors. , 1998, European journal of biochemistry.

[16]  A. Fornace,et al.  p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. , 1998, Cancer research.

[17]  V. Dixit,et al.  TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling , 1998, FEBS letters.

[18]  S. Hetts.  To die or not to die: an overview of apoptosis and its role in disease. , 1998, JAMA.

[19]  J. Bell,et al.  Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. , 1998, Journal of immunology.

[20]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[21]  M. Andreeff,et al.  Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignancies , 1997, British journal of haematology.

[22]  A. Gurney,et al.  A novel receptor for Apo2L/TRAIL contains a truncated death domain , 1997, Current Biology.

[23]  L. Hood,et al.  Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. , 1997, Immunity.

[24]  S. Fulda,et al.  Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells , 1997, Leukemia.

[25]  J. Tschopp,et al.  Characterization of two receptors for TRAIL 1 , 1997 .

[26]  S. Srinivasula,et al.  Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.

[27]  R. Dubose,et al.  Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.

[28]  I. Herr,et al.  The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. , 1997, Cancer research.

[29]  J. Bell,et al.  TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL , 1997, Current Biology.

[30]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[31]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[32]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[33]  T. Gura.  How TRAIL Kills Cancer Cells, But Not Normal Cells , 1997, Science.

[34]  C. Gerharz,et al.  Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[35]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[36]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[37]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[38]  R. Moll,et al.  Chromophilic renal cell carcinoma: cytomorphological and cytogenetic characterisation of four permanent cell lines. , 1996, British Journal of Cancer.

[39]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[40]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[41]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[42]  S. Störkel,et al.  Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma. , 1995, The American journal of pathology.

[43]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[44]  W. Linehan,et al.  Chromosome 17p deletions and p53 mutations in renal cell carcinoma. , 1993, Cancer research.

[45]  S. Störkel,et al.  Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro. , 1993, The American journal of pathology.

[46]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[47]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[48]  P. Palmer,et al.  Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. , 1992, European journal of cancer.

[49]  L. Grochow,et al.  Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. , 1992, Cancer research.

[50]  C. Cordon-Cardo,et al.  Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. , 1991, Cancer research.

[51]  P. Alken,et al.  Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. , 1990, The Journal of urology.

[52]  A. Rudolph,et al.  Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[54]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[55]  P. Krammer.  The tumor strikes back: New data on expression of the CD95(APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology , 1997, Cell Death and Differentiation.

[56]  John Leyden. Webb,et al.  Enzyme and metabolic inhibitors , 1963 .